An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects
Authors:
Open Access
- 26 May 2012
- journal article
- clinical trial
- Published by Springer Nature in Pediatric Nephrology
- Vol. 27 (10) , 1953-1959
Abstract
Background There is limited knowledge of the effectiveness and safety profile of cinacalcet in pediatric patients with secondary hyperparathyroidism (sHPT) treated with dialysis. Methods This was an open-label, single-dose study conducted on 12 pediatric subjects with chronic kidney disease treated with dialysis. Subjects were stratified by four age cohorts and given a single 15-mg oral dose of cinacalcet. Multiple blood samples were collected up to 72 h post-dose for the assessment of serum calcium (Ca), serum intact parathyroid hormone (iPTH), and plasma cinacalcet concentrations. Results Overall, cinacalcet was well tolerated with no serious adverse events. Mean (standard deviation) percentage change in serum Ca over the first 12 h post-dose was −2.93 % (5.70 %) with a nadir of −4.34 % (6.04 %) at 8 h; Ca values returned to baseline by 48 h post-dose. Mean percentage change in iPTH over the first 12 h post-dose was 57.94 % (71.82 %) with a nadir of −35.65 % (55.82 %) at 2 h. There was an inverse relationship between peak serum Ca concentration and body surface area (BSA) (r 2 = 0.41), although no relationship was found between area under the curve and age or BSA. Conclusions These data support future analysis to determine the therapeutic starting dose of cinacalcet for pediatric patients with sHPT on dialysis.Keywords
This publication has 21 references indexed in Scilit:
- Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidismKidney International, 2011
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Cinacalcet HydrochlorideClinical Pharmacokinetics, 2009
- Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidismNephrology Dialysis Transplantation, 2008
- Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidismNephrology Dialysis Transplantation, 2008
- Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients2006
- Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium × PhosphateClinical Journal of the American Society of Nephrology, 2006
- No Effect of Renal Function or Dialysis on Pharmacokinetics of Cinacalcet (Sensipar??/Mimpara??)Clinical Pharmacokinetics, 2005
- Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trialsPediatric Nephrology, 2003
- Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroidNature, 1993
- Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium.Journal of Clinical Investigation, 1989